View Future GrowthBiofrontera 과거 순이익 실적과거 기준 점검 0/6Biofrontera 의 수입은 연평균 -1.2%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 4.9%의 비율로 증가했습니다. 매출은 연평균 13.8%의 비율로 감소해 왔습니다.핵심 정보-1.25%순이익 성장률0.69%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률14.12%매출 성장률-13.81%자기자본이익률-39.05%순이익률-48.98%다음 순이익 업데이트30 Sep 2026최근 과거 실적 업데이트Reported Earnings • Apr 24Full year 2025 earnings released: €1.12 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €1.12 loss per share (further deteriorated from €0.70 loss in FY 2024). Revenue: €13.2m (up 8.3% from FY 2024). Net loss: €6.81m (loss widened 61% from FY 2024). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.공고 • Dec 16+ 3 more updatesBiofrontera AG to Report Fiscal Year 2024 Results on Apr 30, 2025Biofrontera AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Apr 30, 2025공고 • Sep 26Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024Biofrontera AG announced that they will report first half, 2024 results on Sep 30, 2024공고 • May 16Biofrontera AG to Report Q1, 2024 Results on May 31, 2024Biofrontera AG announced that they will report Q1, 2024 results on May 31, 2024공고 • Apr 24Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024Biofrontera AG announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 30, 2024공고 • Nov 07Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023Biofrontera AG announced that they will report Q3, 2023 results on Nov 28, 2023모든 업데이트 보기Recent updatesNew Risk • Jun 02New major risk - Revenue and earnings growthEarnings have declined by 2.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 2.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€14.9m market cap, or US$17.4m).공고 • May 01Biofrontera AG, Annual General Meeting, Jun 10, 2026Biofrontera AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Apr 24Full year 2025 earnings released: €1.12 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €1.12 loss per share (further deteriorated from €0.70 loss in FY 2024). Revenue: €13.2m (up 8.3% from FY 2024). Net loss: €6.81m (loss widened 61% from FY 2024). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.공고 • Oct 24Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG.Biofrontera Inc. (NasdaqCM:BFRI) signed an agreement to acquire US Assets related to Ameluz and RhodoLED of Biofrontera AG on June 30, 2025. The transaction coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, funded the acquisition and transfer costs. Upon completion, Biofrontera Inc. will pay a monthly Ameluz® royalty of 12% in years where Ameluz® revenue in the US is less than $65 million, and 15% in years when revenue exceeds that threshold. The new royalty replaces the former transfer pricing model which required payment of 25% to 35% of the net sales price per tube depending on timing and indication. As part of the agreement, Biofrontera AG will receive a 10% post-money equity stake in Biofrontera Inc., aligning long-term interests between the entities. Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG on October 23, 2025. On completion, Biofrontera Inc. now assumes full responsibility for manufacturing, regulatory, quality management, pharmacovigilance, and commercialization of Ameluz ® and the RhodoLED ® portfolio in the U.S. The Company expects the full transfer of assets and personnel to be completed by late Q4 2025 or early Q1 2026.공고 • Apr 18Biofrontera AG, Annual General Meeting, May 28, 2025Biofrontera AG, Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time.공고 • Dec 16+ 3 more updatesBiofrontera AG to Report Fiscal Year 2024 Results on Apr 30, 2025Biofrontera AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Apr 30, 2025공고 • Nov 24Biofrontera AG announced that it has received $4.2 million in fundingBiofrontera Inc. announced a private placement to issue senior secured convertible note for the gross proceeds of $4,200,000 on November 22, 2024. The transaction included participation from two majority shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder’s discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the note will be automatically converted to common shares if the 10-day volume weighted average price (VWAP) of Company shares on Nasdaq is greater than $2.50, and certain other conditions are met. The Notes contain customary restrictive covenants that, among other things, generally limit the ability of the Company to (i) create liens, (ii) pay dividends or acquire shares of capital stock, (iii) incur indebtedness, or (iv) enter into transactions with affiliates. The foregoing restrictive covenants are subject to a number of important exceptions and qualifications, as set forth in the Notes.공고 • Sep 26Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024Biofrontera AG announced that they will report first half, 2024 results on Sep 30, 2024공고 • Jul 23Biofrontera AG, Annual General Meeting, Aug 28, 2024Biofrontera AG, Annual General Meeting, Aug 28, 2024, at 10:00 W. Europe Standard Time.공고 • May 16Biofrontera AG to Report Q1, 2024 Results on May 31, 2024Biofrontera AG announced that they will report Q1, 2024 results on May 31, 2024공고 • Apr 24Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024Biofrontera AG announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 30, 2024공고 • Nov 07Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023Biofrontera AG announced that they will report Q3, 2023 results on Nov 28, 2023공고 • Jul 14Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023Biofrontera AG announced that they will report first half, 2023 results on Aug 31, 2023공고 • Jul 06Biofrontera Launches Novel Belixos Active CareBiofrontera announced that the active cosmetic series belixos has been extended by the care foam belixos ACTIVE CARE. belixos ACTIVE CARE is a skin-so clothing care foam for irritated and itchy skin that can be used as basic care for atopic dermatitis and psoriasis, as well as for soothing intensive care for everyday skin problems. With its innovative formulation as a foam, it provides a pleasant feeling on the skin without a greasy film and enables particularly gentle application of the high-quality ingredients as a result of the reduced foam formulation. Due to it's innovative nature, Biofrontera was able to register the underlying innovative foam formulation as a patent. As previously in the belixos cosmetics series, the focus is on the traditional medicinal plant Mahonia as an active component. The medicinal plant, which is still quite unknown in European country but has been used for centuries in the medicine of the indigenous people of North America, is known to have anti-inflammatory, antipruritic and antiseptic properties. With the help of Biofrontera's proprietary biocolloid technology, the plant-based active ingredients penetrate very quickly into the epidermis and distribute there in order to unfold their soothing and regenerating effect in this very sensitive layer of skin that is particularly accessible to external influences.공고 • May 30Biofrontera AG to Report Q1, 2023 Results on May 31, 2023Biofrontera AG announced that they will report Q1, 2023 results on May 31, 2023공고 • May 18Biofrontera AG Completes Patient Recruitment of Ameluz Phase I TrialBiofrontera AG announced the successful completion of the Phase I study evaluating the safety and tolerability of Ameluz-PDT for the treatment of actinic keratosis (AK) with 3 tubes of Ameluz. This trial was conducted to expand the approval of Ameluz in the United States so that larger areas of AK-affected skin can be treated in one therapy session. The study involved 100 patients with mild to severe actinic keratosis, each of them receiving the contents of 3 tubes of Ameluz for a field-directed treatment of AK. Illumination was provided by Biofrontera's novel, larger RhodoLED XL lamp. The first results of the study are expected in the fourth quarter of 2023.공고 • May 13Biofrontera AG, Annual General Meeting, Jun 20, 2023Biofrontera AG, Annual General Meeting, Jun 20, 2023, at 11:30 Central European Standard Time. Location: Forum Leverkusen, Agam-Saal, Am Büchelter Hof 9, Leverkusen GermanyReported Earnings • Apr 30Full year 2022 earnings released: €0.77 loss per share (vs €0.69 profit in FY 2021)Full year 2022 results: €0.77 loss per share (down from €0.69 profit in FY 2021). Revenue: €25.7m (down 11% from FY 2021). Net loss: €44.2m (down 215% from profit in FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.매출 및 비용 세부 내역Biofrontera가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이LSE:0DOL 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Mar 2614-710231 Dec 2513-710230 Sep 2523-214431 Mar 251249131 Dec 2412110230 Sep 2418012630 Jun 2422-311831 Mar 2430012831 Dec 2332013830 Sep 2329-913830 Jun 2328-1113831 Mar 2325-2013731 Dec 2226-4412730 Sep 22321118730 Jun 22311024731 Mar 22301529731 Dec 21293834730 Sep 2128-1630630 Jun 2127-1629531 Mar 2129-1226531 Dec 2030-1328530 Sep 2033-1733530 Jun 2033-2237531 Mar 2031-1045531 Dec 1931-744530 Sep 1926144430 Jun 1926840531 Mar 1923-833531 Dec 1821-931430 Sep 1819-1424430 Jun 1816-1522431 Mar 1814-1621431 Dec 1712-1620430 Sep 1711-1821530 Jun 179-1617531 Mar 178-1414531 Dec 166-1112530 Sep 164-99430 Jun 164-78431 Mar 164-97631 Dec 154-117630 Sep 154-1277양질의 수익: 0DOL 은(는) 현재 수익성이 없습니다.이익 마진 증가: 0DOL는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 0DOL은 수익성이 없으며 지난 5년 동안 손실이 연평균 1.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 0DOL의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 0DOL은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(19%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 0DOL는 현재 수익성이 없으므로 자본 수익률이 음수(-39.05%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/01 06:19종가2026/07/28 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biofrontera AG는 6명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Raymond MyersBenchmark CompanyTsvetan KintisheffFirst Berlin Equity Research GmbHThomas FlatenLake Street Capital Markets, LLC3명의 분석가 더 보기
Reported Earnings • Apr 24Full year 2025 earnings released: €1.12 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €1.12 loss per share (further deteriorated from €0.70 loss in FY 2024). Revenue: €13.2m (up 8.3% from FY 2024). Net loss: €6.81m (loss widened 61% from FY 2024). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
공고 • Dec 16+ 3 more updatesBiofrontera AG to Report Fiscal Year 2024 Results on Apr 30, 2025Biofrontera AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Apr 30, 2025
공고 • Sep 26Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024Biofrontera AG announced that they will report first half, 2024 results on Sep 30, 2024
공고 • May 16Biofrontera AG to Report Q1, 2024 Results on May 31, 2024Biofrontera AG announced that they will report Q1, 2024 results on May 31, 2024
공고 • Apr 24Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024Biofrontera AG announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 30, 2024
공고 • Nov 07Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023Biofrontera AG announced that they will report Q3, 2023 results on Nov 28, 2023
New Risk • Jun 02New major risk - Revenue and earnings growthEarnings have declined by 2.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 2.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€14.9m market cap, or US$17.4m).
공고 • May 01Biofrontera AG, Annual General Meeting, Jun 10, 2026Biofrontera AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Apr 24Full year 2025 earnings released: €1.12 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €1.12 loss per share (further deteriorated from €0.70 loss in FY 2024). Revenue: €13.2m (up 8.3% from FY 2024). Net loss: €6.81m (loss widened 61% from FY 2024). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
공고 • Oct 24Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG.Biofrontera Inc. (NasdaqCM:BFRI) signed an agreement to acquire US Assets related to Ameluz and RhodoLED of Biofrontera AG on June 30, 2025. The transaction coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, funded the acquisition and transfer costs. Upon completion, Biofrontera Inc. will pay a monthly Ameluz® royalty of 12% in years where Ameluz® revenue in the US is less than $65 million, and 15% in years when revenue exceeds that threshold. The new royalty replaces the former transfer pricing model which required payment of 25% to 35% of the net sales price per tube depending on timing and indication. As part of the agreement, Biofrontera AG will receive a 10% post-money equity stake in Biofrontera Inc., aligning long-term interests between the entities. Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG on October 23, 2025. On completion, Biofrontera Inc. now assumes full responsibility for manufacturing, regulatory, quality management, pharmacovigilance, and commercialization of Ameluz ® and the RhodoLED ® portfolio in the U.S. The Company expects the full transfer of assets and personnel to be completed by late Q4 2025 or early Q1 2026.
공고 • Apr 18Biofrontera AG, Annual General Meeting, May 28, 2025Biofrontera AG, Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time.
공고 • Dec 16+ 3 more updatesBiofrontera AG to Report Fiscal Year 2024 Results on Apr 30, 2025Biofrontera AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Apr 30, 2025
공고 • Nov 24Biofrontera AG announced that it has received $4.2 million in fundingBiofrontera Inc. announced a private placement to issue senior secured convertible note for the gross proceeds of $4,200,000 on November 22, 2024. The transaction included participation from two majority shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder’s discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the note will be automatically converted to common shares if the 10-day volume weighted average price (VWAP) of Company shares on Nasdaq is greater than $2.50, and certain other conditions are met. The Notes contain customary restrictive covenants that, among other things, generally limit the ability of the Company to (i) create liens, (ii) pay dividends or acquire shares of capital stock, (iii) incur indebtedness, or (iv) enter into transactions with affiliates. The foregoing restrictive covenants are subject to a number of important exceptions and qualifications, as set forth in the Notes.
공고 • Sep 26Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024Biofrontera AG announced that they will report first half, 2024 results on Sep 30, 2024
공고 • Jul 23Biofrontera AG, Annual General Meeting, Aug 28, 2024Biofrontera AG, Annual General Meeting, Aug 28, 2024, at 10:00 W. Europe Standard Time.
공고 • May 16Biofrontera AG to Report Q1, 2024 Results on May 31, 2024Biofrontera AG announced that they will report Q1, 2024 results on May 31, 2024
공고 • Apr 24Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024Biofrontera AG announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 30, 2024
공고 • Nov 07Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023Biofrontera AG announced that they will report Q3, 2023 results on Nov 28, 2023
공고 • Jul 14Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023Biofrontera AG announced that they will report first half, 2023 results on Aug 31, 2023
공고 • Jul 06Biofrontera Launches Novel Belixos Active CareBiofrontera announced that the active cosmetic series belixos has been extended by the care foam belixos ACTIVE CARE. belixos ACTIVE CARE is a skin-so clothing care foam for irritated and itchy skin that can be used as basic care for atopic dermatitis and psoriasis, as well as for soothing intensive care for everyday skin problems. With its innovative formulation as a foam, it provides a pleasant feeling on the skin without a greasy film and enables particularly gentle application of the high-quality ingredients as a result of the reduced foam formulation. Due to it's innovative nature, Biofrontera was able to register the underlying innovative foam formulation as a patent. As previously in the belixos cosmetics series, the focus is on the traditional medicinal plant Mahonia as an active component. The medicinal plant, which is still quite unknown in European country but has been used for centuries in the medicine of the indigenous people of North America, is known to have anti-inflammatory, antipruritic and antiseptic properties. With the help of Biofrontera's proprietary biocolloid technology, the plant-based active ingredients penetrate very quickly into the epidermis and distribute there in order to unfold their soothing and regenerating effect in this very sensitive layer of skin that is particularly accessible to external influences.
공고 • May 30Biofrontera AG to Report Q1, 2023 Results on May 31, 2023Biofrontera AG announced that they will report Q1, 2023 results on May 31, 2023
공고 • May 18Biofrontera AG Completes Patient Recruitment of Ameluz Phase I TrialBiofrontera AG announced the successful completion of the Phase I study evaluating the safety and tolerability of Ameluz-PDT for the treatment of actinic keratosis (AK) with 3 tubes of Ameluz. This trial was conducted to expand the approval of Ameluz in the United States so that larger areas of AK-affected skin can be treated in one therapy session. The study involved 100 patients with mild to severe actinic keratosis, each of them receiving the contents of 3 tubes of Ameluz for a field-directed treatment of AK. Illumination was provided by Biofrontera's novel, larger RhodoLED XL lamp. The first results of the study are expected in the fourth quarter of 2023.
공고 • May 13Biofrontera AG, Annual General Meeting, Jun 20, 2023Biofrontera AG, Annual General Meeting, Jun 20, 2023, at 11:30 Central European Standard Time. Location: Forum Leverkusen, Agam-Saal, Am Büchelter Hof 9, Leverkusen Germany
Reported Earnings • Apr 30Full year 2022 earnings released: €0.77 loss per share (vs €0.69 profit in FY 2021)Full year 2022 results: €0.77 loss per share (down from €0.69 profit in FY 2021). Revenue: €25.7m (down 11% from FY 2021). Net loss: €44.2m (down 215% from profit in FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.